<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;v=2.18.0.post9+e462414&amp;fc=20230708114047&amp;utm_campaign=pubmed-2&amp;ff=20250401101145&amp;utm_source=Chrome
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;v=2.18.0.post9+e462414&amp;fc=20230708114047&amp;utm_campaign=pubmed-2&amp;ff=20250401101145&amp;utm_source=Chrome" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Tue, 01 Apr 2025 14:11:47 +0000</lastbuilddate>
<pubDate>Tue, 01 Apr 2025 06:00:00 -0400</pubDate>
<ttl>120</ttl>
<item>
<title>Learning from epidemiology: atrial fibrillation, peripheral artery disease, and twin pregnancy</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40166867/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250401101145&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Apr 1;46(13):1173-1177. doi: 10.1093/eurheartj/ehaf138.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40166867/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250401101145&v=2.18.0.post9+e462414">40166867</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehaf138>10.1093/eurheartj/ehaf138</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40166867</guid>
<pubDate>Tue, 01 Apr 2025 06:00:00 -0400</pubDate>
<dc:creator>Filippo Crea</dc:creator>
<dc:date>2025-04-01</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Learning from epidemiology: atrial fibrillation, peripheral artery disease, and twin pregnancy</dc:title>
<dc:identifier>pmid:40166867</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehaf138</dc:identifier>
</item>
<item>
<title>Lymphatic Endothelial Branched-Chain Amino Acid Catabolic Defects Undermine Cardiac Lymphatic Integrity and Drive HFpEF</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40166847/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250401101145&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Our study provides evidence that cardiac lymphatic disruption, driven by impaired BCAA catabolism in LECs, is a key factor contributing to HFpEF. These findings unravel the crucial role of BCAA catabolism in modulating lymphatic biology, and suggest that preserving cardiac lymphatic integrity may present a novel therapeutic strategy for HFpEF.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2025 Apr 1. doi: 10.1161/CIRCULATIONAHA.124.071741. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Heart failure with preserved ejection fraction (HFpEF) has become the most prevalent type of heart failure, but effective treatments are lacking. Cardiac lymphatics play a crucial role in maintaining heart health by draining fluids and immune cells. However, their involvement in HFpEF remains largely unexplored.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We examined cardiac lymphatic alterations in mice with HFpEF with comorbid obesity and hypertension, and in heart tissues from patients with HFpEF. Using genetically engineered mouse models and various cellular and molecular techniques, we investigated the role of cardiac lymphatics in HFpEF and the underlying mechanisms.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: In mice with HFpEF, cardiac lymphatics displayed substantial structural and functional anomalies, including decreased lymphatic endothelial cell (LEC) density, vessel fragmentation, reduced branch connections, and impaired capacity to drain fluids and immune cells. LEC numbers and marker expression levels were also decreased in heart tissues from patients with HFpEF. Stimulating lymphangiogenesis with an adeno-associated virus expressing an engineered variant of vascular endothelial growth factor C (VEGFC<sup>C156S</sup>) that selectively activates vascular endothelial growth factor receptor 3 (VEGFR3) in LECs restored cardiac lymphatic integrity and substantially alleviated HFpEF. Through discovery-driven approaches, defective branched-chain amino acid (BCAA) catabolism was identified as a predominant metabolic signature in HFpEF cardiac LECs. Overexpression of branched-chain ketoacid dehydrogenase kinase (encoded by the <i>Bckdk</i> gene), which inactivates branched-chain ketoacid dehydrogenase (the rate-limiting enzyme in BCAA catabolism), resulted in spontaneous lymphangiogenic defects in LECs. In mice, inducible <i>Bckdk</i> gene deletion in LECs to enhance their BCAA catabolism preserved cardiac lymphatic integrity and protected against HFpEF. BCAA catabolic defects caused ligand-independent phosphorylation of VEGFR3 in the cytoplasm by Src kinase, leading to lysosomal degradation of VEGFR3 instead of its trafficking to the cell membrane. Reduced VEGFR3 availability on the cell surface impeded downstream Akt (protein kinase B) activation, hindered glucose uptake and utilization, and inhibited lymphangiogenesis in LECs with BCAA catabolic defects.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Our study provides evidence that cardiac lymphatic disruption, driven by impaired BCAA catabolism in LECs, is a key factor contributing to HFpEF. These findings unravel the crucial role of BCAA catabolism in modulating lymphatic biology, and suggest that preserving cardiac lymphatic integrity may present a novel therapeutic strategy for HFpEF.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40166847/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250401101145&v=2.18.0.post9+e462414">40166847</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.071741>10.1161/CIRCULATIONAHA.124.071741</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40166847</guid>
<pubDate>Tue, 01 Apr 2025 06:00:00 -0400</pubDate>
<dc:creator>Xiong Guo</dc:creator>
<dc:creator>Chong Huang</dc:creator>
<dc:creator>Ling Zhang</dc:creator>
<dc:creator>Guangyu Hu</dc:creator>
<dc:creator>Yunhui Du</dc:creator>
<dc:creator>Xiyao Chen</dc:creator>
<dc:creator>Fangfang Sun</dc:creator>
<dc:creator>Tongzheng Li</dc:creator>
<dc:creator>Zhe Cui</dc:creator>
<dc:creator>Congye Li</dc:creator>
<dc:creator>Yongzhen Guo</dc:creator>
<dc:creator>Wenjun Yan</dc:creator>
<dc:creator>Yunlong Xia</dc:creator>
<dc:creator>Shan Wang</dc:creator>
<dc:creator>Hui Liu</dc:creator>
<dc:creator>Zhiyuan Liu</dc:creator>
<dc:creator>Zhen Lin</dc:creator>
<dc:creator>Xinyi Wang</dc:creator>
<dc:creator>Zhengyang Wang</dc:creator>
<dc:creator>Fuyang Zhang</dc:creator>
<dc:creator>Ling Tao</dc:creator>
<dc:date>2025-04-01</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Lymphatic Endothelial Branched-Chain Amino Acid Catabolic Defects Undermine Cardiac Lymphatic Integrity and Drive HFpEF</dc:title>
<dc:identifier>pmid:40166847</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.071741</dc:identifier>
</item>
<item>
<title>A Randomized Controlled Trial of Thoracentesis in Acute Heart Failure</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40166829/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250401101145&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: For patients with acute heart failure and pleural effusion, a strategy of upfront routine thoracentesis in addition to standard medical therapy did not increase days alive out of the hospital for 90 days, all-cause mortality, or duration of index admission. The current findings lay the groundwork for future research to confirm the results.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2025 Apr 1. doi: 10.1161/CIRCULATIONAHA.124.073521. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: TAP-IT (Thoracentesis to Alleviate Cardiac Pleural Effusion-Interventional Trial) investigated the effect of therapeutic thoracentesis in addition to standard medical therapy in patients with acute heart failure and sizeable pleural effusion.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: This multicenter, unblinded, randomized controlled trial, conducted between August 31, 2021, and March 22, 2024, included patients with acute heart failure, left ventricular ejection fraction ≤45%, and non-negligible pleural effusion. Patients with very large effusions (more than two-thirds of the hemithorax) were excluded. Participants were randomly assigned 1:1 to upfront ultrasound-guided pleural pigtail catheter thoracentesis in addition to standard medical therapy or standard medical therapy alone. The primary outcome was days alive out of the hospital over the following 90 days; key secondary outcomes included length of admission and 90-day all-cause mortality. All outcomes were analyzed according to the intention-to-treat principle.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: A total of 135 patients (median age, 81 years [25th; 75th percentile, 75; 83]; 33% female; median left ventricular ejection fraction, 25% [25th; 75th percentile, 20%; 35%]) were randomized to either thoracentesis (n=68) or standard medical therapy (n=67). The thoracentesis group had a median of 84 days (77; 86) alive out of the hospital over the following 90 days compared with 82 days (73; 86) in the control group (<i>P</i>=0.42). The mortality rate was 13% in both groups, with no difference in survival probability (<i>P</i>=0.90). There were no differences in the duration of the index admission (control group median, 5 days [3; 8]; thoracentesis group median, 5 days [3; 7; <i>P</i>=0.69]). Major complications occurred in 1% of thoracenteses performed during the study period.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: For patients with acute heart failure and pleural effusion, a strategy of upfront routine thoracentesis in addition to standard medical therapy did not increase days alive out of the hospital for 90 days, all-cause mortality, or duration of index admission. The current findings lay the groundwork for future research to confirm the results.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT05017753.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40166829/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250401101145&v=2.18.0.post9+e462414">40166829</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.073521>10.1161/CIRCULATIONAHA.124.073521</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40166829</guid>
<pubDate>Tue, 01 Apr 2025 06:00:00 -0400</pubDate>
<dc:creator>Signe Glargaard</dc:creator>
<dc:creator>Jakob Hartvig Thomsen</dc:creator>
<dc:creator>Christian Tuxen</dc:creator>
<dc:creator>Matias Greve Lindholm</dc:creator>
<dc:creator>Christian Axel Bang</dc:creator>
<dc:creator>Morten Schou</dc:creator>
<dc:creator>Kasper Iversen</dc:creator>
<dc:creator>Rasmus Vedby Rasmussen</dc:creator>
<dc:creator>Brian Bridal Løgstrup</dc:creator>
<dc:creator>Søren Vraa</dc:creator>
<dc:creator>Nis Stride</dc:creator>
<dc:creator>Ekim Seven</dc:creator>
<dc:creator>Anders Barasa</dc:creator>
<dc:creator>Marlene Tofterup</dc:creator>
<dc:creator>Dan Eik Høfsten</dc:creator>
<dc:creator>Kasper Rossing</dc:creator>
<dc:creator>Lars Køber</dc:creator>
<dc:creator>Finn Gustafsson</dc:creator>
<dc:creator>Jens Jakob Thune</dc:creator>
<dc:date>2025-04-01</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>A Randomized Controlled Trial of Thoracentesis in Acute Heart Failure</dc:title>
<dc:identifier>pmid:40166829</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.073521</dc:identifier>
</item>
<item>
<title>Olmesartan Restores &lt;em>;LMNA&lt;/em>; Function in Haploinsufficient Cardiomyocytes</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40166828/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250401101145&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: In silico screening followed by in vitro validation with induced pluripotent stem cell-derived models can be an efficient approach to identifying repositionable therapies for monogenic cardiomyopathies.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2025 Apr 1. doi: 10.1161/CIRCULATIONAHA.121.058621. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Gene mutations are responsible for a sizeable proportion of cases of heart failure. However, the number of patients with any specific mutation is small. Repositioning of existing US Food and Drug Administration-approved compounds to target specific mutations is a promising approach to efficient identification of new therapies for these patients.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: The National Institutes of Health Library of Integrated Network-Based Cellular Signatures database was interrogated to identify US Food and Drug Administration-approved compounds that demonstrated the ability to reverse the transcriptional effects of <i>LMNA</i> knockdown. Top hits from this screening were validated in vitro with patient-specific induced pluripotent stem cell-derived cardiomyocytes combined with force measurement, gene expression profiling, electrophysiology, and protein expression analysis.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Several angiotensin receptor blockers were identified from our in silico screen. Of these, olmesartan significantly elevated the expression of sarcomeric genes and rate and force of contraction and ameliorated arrhythmogenic potential. In addition, olmesartan exhibited the ability to reduce phosphorylation of extracellular signal-regulated kinase 1 in <i>LMNA</i>-mutant induced pluripotent stem cell-derived cardiomyocytes.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In silico screening followed by in vitro validation with induced pluripotent stem cell-derived models can be an efficient approach to identifying repositionable therapies for monogenic cardiomyopathies.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40166828/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250401101145&v=2.18.0.post9+e462414">40166828</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.121.058621>10.1161/CIRCULATIONAHA.121.058621</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40166828</guid>
<pubDate>Tue, 01 Apr 2025 06:00:00 -0400</pubDate>
<dc:creator>Eric J Kort</dc:creator>
<dc:creator>Nazish Sayed</dc:creator>
<dc:creator>Chun Liu</dc:creator>
<dc:creator>Gema Mondéjar-Parreño</dc:creator>
<dc:creator>Jens Forsberg</dc:creator>
<dc:creator>Emily Eugster</dc:creator>
<dc:creator>Sean M Wu</dc:creator>
<dc:creator>Joseph C Wu</dc:creator>
<dc:creator>Stefan Jovinge</dc:creator>
<dc:date>2025-04-01</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Olmesartan Restores &lt;em>;LMNA&lt;/em>; Function in Haploinsufficient Cardiomyocytes</dc:title>
<dc:identifier>pmid:40166828</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.121.058621</dc:identifier>
</item>
<item>
<title>Factor XI inhibitors for the prevention and treatment of venous and arterial thromboembolism</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40164778/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250401101145&amp;v=2.18.0.post9+e462414
      <description>Therapeutic anticoagulation is essential to prevent and treat venous and arterial thromboembolism. The available agents target coagulation factors involved in thrombus formation but are associated with an increased risk of bleeding. Factor XI plays a minor role in haemostasis but contributes substantially to thrombus expansion, making it an attractive target to mitigate bleeding while maintaining antithrombotic efficacy. Various novel inhibitors, including antisense oligonucleotides, monoclonal...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2025 Mar 31. doi: 10.1038/s41569-025-01144-z. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Therapeutic anticoagulation is essential to prevent and treat venous and arterial thromboembolism. The available agents target coagulation factors involved in thrombus formation but are associated with an increased risk of bleeding. Factor XI plays a minor role in haemostasis but contributes substantially to thrombus expansion, making it an attractive target to mitigate bleeding while maintaining antithrombotic efficacy. Various novel inhibitors, including antisense oligonucleotides, monoclonal antibodies and small molecules, have been developed. Phase II trials in orthopaedic surgery showed dose-dependent reductions in venous thromboembolism without significantly increasing bleeding compared with enoxaparin. In the first phase III trial of a small-molecule inhibitor of activated factor XI in patients with atrial fibrillation, asundexian was associated with a reduction in bleeding but also a higher risk of stroke, compared with apixaban. Factor XI inhibitors appear safe and hold promise for secondary prevention in myocardial infarction and ischaemic stroke, with ongoing phase III trials assessing their broader efficacy and safety. This Review discusses the rationale, pharmacology, evidence and future directions of factor XI inhibitors across various clinical settings.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40164778/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250401101145&v=2.18.0.post9+e462414">40164778</a> | DOI:<a href=https://doi.org/10.1038/s41569-025-01144-z>10.1038/s41569-025-01144-z</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40164778</guid>
<pubDate>Mon, 31 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Davide Capodanno</dc:creator>
<dc:creator>John H Alexander</dc:creator>
<dc:creator>M Cecilia Bahit</dc:creator>
<dc:creator>John W Eikelboom</dc:creator>
<dc:creator>C Michael Gibson</dc:creator>
<dc:creator>Shaun G Goodman</dc:creator>
<dc:creator>Vijay Kunadian</dc:creator>
<dc:creator>Gregory Y H Lip</dc:creator>
<dc:creator>Renato D Lopes</dc:creator>
<dc:creator>Roxana Mehran</dc:creator>
<dc:creator>Shamir R Mehta</dc:creator>
<dc:creator>Manesh R Patel</dc:creator>
<dc:creator>Jonathan P Piccini</dc:creator>
<dc:creator>Sunil V Rao</dc:creator>
<dc:creator>Christian T Ruff</dc:creator>
<dc:creator>P Gabriel Steg</dc:creator>
<dc:creator>Jeffrey I Weitz</dc:creator>
<dc:creator>Dominick J Angiolillo</dc:creator>
<dc:date>2025-03-31</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Factor XI inhibitors for the prevention and treatment of venous and arterial thromboembolism</dc:title>
<dc:identifier>pmid:40164778</dc:identifier>
<dc:identifier>doi:10.1038/s41569-025-01144-z</dc:identifier>
</item>
<item>
<title>Cardiac Biomarkers in Patients with Asymptomatic Severe Aortic Stenosis: Analysis from the EARLY TAVR Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40163596/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250401101145&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: In patients with asymptomatic severe high gradient AS, higher NT-proBNP and hs-cTnT levels were broadly associated with higher event rates as expected. However, the relative benefit of an early TAVR strategy was consistent regardless of baseline biomarker levels and, contrary to our hypothesis, tended to be more pronounced in those with the lowest biomarker levels. These findings suggest limited value for single measurements of these biomarkers to guide the timing of TAVR in...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2025 Mar 31. doi: 10.1161/CIRCULATIONAHA.125.074425. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: The EARLY TAVR trial demonstrated that early transcatheter aortic valve replacement (TAVR) intervention was superior to clinical surveillance (CS) with delayed TAVR in patients with asymptomatic, severe aortic stenosis (AS). Cardiac biomarkers are associated with maladaptive remodeling, symptom onset, and worse outcomes after TAVR. Whether elevated biomarkers identify asymptomatic patients more likely to benefit from early intervention is unknown.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: A core laboratory measured N-terminal pro-B-type natriuretic peptide (NT-proBNP) and high sensitivity cardiac troponin T (hs-cTnT). Associations between biomarker levels and risk of the trial primary endpoint (death, stroke, or unplanned cardiovascular hospitalization) and other secondary endpoints were examined with Kaplan-Meier curves and Cox proportional hazard models. Interaction tests were performed to assess whether the treatment effect of early TAVR, compared with CS, differed according to biomarker levels.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Among 901 patients randomized in EARLY TAVR, 798 (89%) had biospecimens measured (median NT-proBNP 287 [145, 601]; median hs-cTnT 14.6 [10.5, 21.0]). Higher levels of NT-proBNP and hs-cTnT were broadly associated with higher event rates for multiple endpoints. In general, there was no significant interaction between baseline biomarkers and treatment group with respect to any composite or individual endpoint examined, although trends broadly demonstrated a greater relative benefit of early TAVR at lower biomarker levels. There was a significant interaction between hs-cTnT and treatment group with respect to death or heart failure hospitalization (HFH) (interaction p=0.04) and HFH alone (interaction p=0.03) such that the relative benefit of early TAVR was greater for patients with normal, rather than elevated, levels of hs-cTnT at baseline. For some endpoints, higher baseline NT-proBNP was associated with numerically greater absolute risk reduction with early TAVR than lower NT-proBNP levels.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In patients with asymptomatic severe high gradient AS, higher NT-proBNP and hs-cTnT levels were broadly associated with higher event rates as expected. However, the relative benefit of an early TAVR strategy was consistent regardless of baseline biomarker levels and, contrary to our hypothesis, tended to be more pronounced in those with the lowest biomarker levels. These findings suggest limited value for single measurements of these biomarkers to guide the timing of TAVR in asymptomatic patients.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40163596/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250401101145&v=2.18.0.post9+e462414">40163596</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.125.074425>10.1161/CIRCULATIONAHA.125.074425</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40163596</guid>
<pubDate>Mon, 31 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Brian R Lindman</dc:creator>
<dc:creator>Philippe Pibarot</dc:creator>
<dc:creator>Allan Schwartz</dc:creator>
<dc:creator>J Bradley Oldemeyer</dc:creator>
<dc:creator>Yan Ru Su</dc:creator>
<dc:creator>Kashish Goel</dc:creator>
<dc:creator>David J Cohen</dc:creator>
<dc:creator>William F Fearon</dc:creator>
<dc:creator>Vasilis Babaliaros</dc:creator>
<dc:creator>David Daniels</dc:creator>
<dc:creator>Adnan Chhatriwalla</dc:creator>
<dc:creator>Hussam S Suradi</dc:creator>
<dc:creator>Pinak Shah</dc:creator>
<dc:creator>Molly Szerlip</dc:creator>
<dc:creator>Michael J Mack</dc:creator>
<dc:creator>Thom Dahle</dc:creator>
<dc:creator>William W O'Neill</dc:creator>
<dc:creator>Charles J Davidson</dc:creator>
<dc:creator>Raj Makkar</dc:creator>
<dc:creator>Tej Sheth</dc:creator>
<dc:creator>Jeremiah Depta</dc:creator>
<dc:creator>James T DeVries</dc:creator>
<dc:creator>Jeffrey Southard</dc:creator>
<dc:creator>Andrei Pop</dc:creator>
<dc:creator>Paul Sorajja</dc:creator>
<dc:creator>Rebecca T Hahn</dc:creator>
<dc:creator>Yanglu Zhao</dc:creator>
<dc:creator>Martin B Leon</dc:creator>
<dc:creator>Philippe Généreux</dc:creator>
<dc:creator>EARLY TAVR Trial Executive Committee and Study Investigators</dc:creator>
<dc:date>2025-03-31</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Cardiac Biomarkers in Patients with Asymptomatic Severe Aortic Stenosis: Analysis from the EARLY TAVR Trial</dc:title>
<dc:identifier>pmid:40163596</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.125.074425</dc:identifier>
</item>
<item>
<title>Correction to: 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40163565/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250401101145&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2025 Apr;151(13):e865. doi: 10.1161/CIR.0000000000001328. Epub 2025 Mar 31.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40163565/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250401101145&v=2.18.0.post9+e462414">40163565</a> | DOI:<a href=https://doi.org/10.1161/CIR.0000000000001328>10.1161/CIR.0000000000001328</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40163565</guid>
<pubDate>Mon, 31 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Sunil V Rao</dc:creator>
<dc:creator>Michelle L O'Donoghue</dc:creator>
<dc:creator>Marc Ruel</dc:creator>
<dc:creator>Tanveer Rab</dc:creator>
<dc:creator>Jaqueline E Tamis-Holland</dc:creator>
<dc:creator>John H Alexander</dc:creator>
<dc:creator>Usman Baber</dc:creator>
<dc:creator>Heather Baker</dc:creator>
<dc:creator>Mauricio G Cohen</dc:creator>
<dc:creator>Mercedes Cruz-Ruiz</dc:creator>
<dc:creator>Leslie L Davis</dc:creator>
<dc:creator>James A de Lemos</dc:creator>
<dc:creator>Tracy A DeWald</dc:creator>
<dc:creator>Islam Y Elgendy</dc:creator>
<dc:creator>Dmitriy N Feldman</dc:creator>
<dc:creator>Abhinav Goyal</dc:creator>
<dc:creator>Ijeoma Isiadinso</dc:creator>
<dc:creator>Venu Menon</dc:creator>
<dc:creator>David A Morrow</dc:creator>
<dc:creator>Debabrata Mukherjee</dc:creator>
<dc:creator>Elke Platz</dc:creator>
<dc:creator>Susan B Promes</dc:creator>
<dc:creator>Sigrid Sandner</dc:creator>
<dc:creator>Yader Sandoval</dc:creator>
<dc:creator>Rachel Schunder</dc:creator>
<dc:creator>Binita Shah</dc:creator>
<dc:creator>Jason P Stopyra</dc:creator>
<dc:creator>Amy W Talbot</dc:creator>
<dc:creator>Pam R Taub</dc:creator>
<dc:creator>Marlene S Williams</dc:creator>
<dc:date>2025-03-31</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Correction to: 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines</dc:title>
<dc:identifier>pmid:40163565</dc:identifier>
<dc:identifier>doi:10.1161/CIR.0000000000001328</dc:identifier>
</item>
<item>
<title>The Future Is Now: Paradigm Shifts in Heart Transplantation in the United States</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40163564/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250401101145&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2025 Apr;151(13):910-912. doi: 10.1161/CIRCULATIONAHA.125.073544. Epub 2025 Mar 31.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40163564/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250401101145&v=2.18.0.post9+e462414">40163564</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.125.073544>10.1161/CIRCULATIONAHA.125.073544</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40163564</guid>
<pubDate>Mon, 31 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Terrence M Yau</dc:creator>
<dc:creator>Subodh Verma</dc:creator>
<dc:date>2025-03-31</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>The Future Is Now: Paradigm Shifts in Heart Transplantation in the United States</dc:title>
<dc:identifier>pmid:40163564</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.125.073544</dc:identifier>
</item>
<item>
<title>Correction to: Prenatal Lipopolysaccharides Exposure Induces Transgenerational Inheritance of Hypertension</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40163563/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250401101145&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2025 Apr;151(13):e866. doi: 10.1161/CIR.0000000000001325. Epub 2025 Mar 31.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40163563/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250401101145&v=2.18.0.post9+e462414">40163563</a> | DOI:<a href=https://doi.org/10.1161/CIR.0000000000001325>10.1161/CIR.0000000000001325</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40163563</guid>
<pubDate>Mon, 31 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Nian Cao</dc:creator>
<dc:creator>Cong Lan</dc:creator>
<dc:creator>Caiyu Chen</dc:creator>
<dc:creator>Zaicheng Xu</dc:creator>
<dc:creator>Hao Luo</dc:creator>
<dc:creator>Shuo Zheng</dc:creator>
<dc:creator>Xue Gong</dc:creator>
<dc:creator>Hongmei Ren</dc:creator>
<dc:creator>Zhuxin Li</dc:creator>
<dc:creator>Shuang Qu</dc:creator>
<dc:creator>Cheng Yu</dc:creator>
<dc:creator>Jining Yang</dc:creator>
<dc:creator>Pedro A Jose</dc:creator>
<dc:creator>Yundai Chen</dc:creator>
<dc:creator>Gengze Wu</dc:creator>
<dc:creator>Cuimei Hu</dc:creator>
<dc:creator>Junyi Yu</dc:creator>
<dc:creator>Chunyu Zeng</dc:creator>
<dc:date>2025-03-31</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Correction to: Prenatal Lipopolysaccharides Exposure Induces Transgenerational Inheritance of Hypertension</dc:title>
<dc:identifier>pmid:40163563</dc:identifier>
<dc:identifier>doi:10.1161/CIR.0000000000001325</dc:identifier>
</item>
<item>
<title>Correction to: Clinical Considerations for Competitive Sports Participation for Athletes With Cardiovascular Abnormalities: A Scientific Statement From the American Heart Association and American College of Cardiology</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40163562/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250401101145&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2025 Apr;151(13):e864. doi: 10.1161/CIR.0000000000001326. Epub 2025 Mar 31.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40163562/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250401101145&v=2.18.0.post9+e462414">40163562</a> | DOI:<a href=https://doi.org/10.1161/CIR.0000000000001326>10.1161/CIR.0000000000001326</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40163562</guid>
<pubDate>Mon, 31 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Jonathan H Kim</dc:creator>
<dc:creator>Aaron L Baggish</dc:creator>
<dc:creator>Benjamin D Levine</dc:creator>
<dc:creator>Michael J Ackerman</dc:creator>
<dc:creator>Sharlene M Day</dc:creator>
<dc:creator>Elizabeth H Dineen</dc:creator>
<dc:creator>J Sawalla Guseh</dc:creator>
<dc:creator>Andre La Gerche</dc:creator>
<dc:creator>Rachel Lampert</dc:creator>
<dc:creator>Matthew W Martinez</dc:creator>
<dc:creator>Michael Papadakis</dc:creator>
<dc:creator>Dermot M Phelan</dc:creator>
<dc:creator>Keri M Shafer</dc:creator>
<dc:creator>American Heart Association Leadership Committee of the Council on Clinical Cardiology; Council on Basic Cardiovascular Sciences; Council on Cardiovascular and Stroke Nursing; Council on Cardiovascular Surgery and Anesthesia; Council on Peripheral Vascular Disease; and American College of Cardiology</dc:creator>
<dc:date>2025-03-31</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Correction to: Clinical Considerations for Competitive Sports Participation for Athletes With Cardiovascular Abnormalities: A Scientific Statement From the American Heart Association and American College of Cardiology</dc:title>
<dc:identifier>pmid:40163562</dc:identifier>
<dc:identifier>doi:10.1161/CIR.0000000000001326</dc:identifier>
</item>
<item>
<title>Correction to: Update on Diagnosis and Management of Kawasaki Disease: A Scientific Statement From the American Heart Association</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40163561/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250401101145&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2025 Apr;151(13):e863. doi: 10.1161/CIR.0000000000001324. Epub 2025 Mar 31.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40163561/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250401101145&v=2.18.0.post9+e462414">40163561</a> | DOI:<a href=https://doi.org/10.1161/CIR.0000000000001324>10.1161/CIR.0000000000001324</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40163561</guid>
<pubDate>Mon, 31 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Pei-Ni Jone</dc:creator>
<dc:creator>Adriana Tremoulet</dc:creator>
<dc:creator>Nadine Choueiter</dc:creator>
<dc:creator>Samuel R Dominguez</dc:creator>
<dc:creator>Ashraf S Harahsheh</dc:creator>
<dc:creator>Yoshihide Mitani</dc:creator>
<dc:creator>Meghan Zimmerman</dc:creator>
<dc:creator>Ming-Tai Lin</dc:creator>
<dc:creator>Kevin G Friedman</dc:creator>
<dc:creator>American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee of the Council on Lifelong Congenital Heart Disease and Heart Health in the Young; Council on Cardiovascular and Stroke Nursing; Council on Cardiovascular Radiology and Intervention; and Council on Clinical Cardiology</dc:creator>
<dc:date>2025-03-31</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Correction to: Update on Diagnosis and Management of Kawasaki Disease: A Scientific Statement From the American Heart Association</dc:title>
<dc:identifier>pmid:40163561</dc:identifier>
<dc:identifier>doi:10.1161/CIR.0000000000001324</dc:identifier>
</item>
<item>
<title>Response by Yu and Cheng to Letter Regarding Article, "Effect of Colchicine on Coronary Plaque Stability in Acute Coronary Syndrome as Assessed by Optical Coherence Tomography: The COLOCT Randomized Clinical Trial"</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40163560/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250401101145&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2025 Apr;151(13):e769-e770. doi: 10.1161/CIRCULATIONAHA.124.073362. Epub 2025 Mar 31.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40163560/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250401101145&v=2.18.0.post9+e462414">40163560</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.073362>10.1161/CIRCULATIONAHA.124.073362</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40163560</guid>
<pubDate>Mon, 31 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Miao Yu</dc:creator>
<dc:creator>Xiang Cheng</dc:creator>
<dc:date>2025-03-31</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Response by Yu and Cheng to Letter Regarding Article, "Effect of Colchicine on Coronary Plaque Stability in Acute Coronary Syndrome as Assessed by Optical Coherence Tomography: The COLOCT Randomized Clinical Trial"</dc:title>
<dc:identifier>pmid:40163560</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.073362</dc:identifier>
</item>
<item>
<title>Return to Play With Genetic Heart Disease: The Importance of Developing a Personalized Emergency Action Plan</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40163559/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250401101145&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2025 Apr;151(13):893-895. doi: 10.1161/CIRCULATIONAHA.124.072830. Epub 2025 Mar 31.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40163559/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250401101145&v=2.18.0.post9+e462414">40163559</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.072830>10.1161/CIRCULATIONAHA.124.072830</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40163559</guid>
<pubDate>Mon, 31 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Belinda Gray</dc:creator>
<dc:creator>Rachel Lampert</dc:creator>
<dc:creator>Michael Papadakis</dc:creator>
<dc:date>2025-03-31</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Return to Play With Genetic Heart Disease: The Importance of Developing a Personalized Emergency Action Plan</dc:title>
<dc:identifier>pmid:40163559</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.072830</dc:identifier>
</item>
<item>
<title>Letter by Kakizaki and Räber Regarding Article, "Effect of Colchicine on Coronary Plaque Stability in Acute Coronary Syndrome as Assessed by Optical Coherence Tomography: The COLOCT Randomized Clinical Trial"</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40163558/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250401101145&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2025 Apr;151(13):e767-e768. doi: 10.1161/CIRCULATIONAHA.124.072950. Epub 2025 Mar 31.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40163558/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250401101145&v=2.18.0.post9+e462414">40163558</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.072950>10.1161/CIRCULATIONAHA.124.072950</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40163558</guid>
<pubDate>Mon, 31 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Ryota Kakizaki</dc:creator>
<dc:creator>Lorenz Räber</dc:creator>
<dc:date>2025-03-31</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Letter by Kakizaki and Räber Regarding Article, "Effect of Colchicine on Coronary Plaque Stability in Acute Coronary Syndrome as Assessed by Optical Coherence Tomography: The COLOCT Randomized Clinical Trial"</dc:title>
<dc:identifier>pmid:40163558</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.072950</dc:identifier>
</item>
<item>
<title>Paternal Cardiac Lesion Induces Cardiac Adaptation in Offspring</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40163557/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250401101145&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2025 Apr;151(13):968-971. doi: 10.1161/CIRCULATIONAHA.124.070323. Epub 2025 Mar 31.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40163557/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250401101145&v=2.18.0.post9+e462414">40163557</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.070323>10.1161/CIRCULATIONAHA.124.070323</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40163557</guid>
<pubDate>Mon, 31 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Benedetta Coppe</dc:creator>
<dc:creator>María Galardi-Castilla</dc:creator>
<dc:creator>Andrés Sanz-Morejón</dc:creator>
<dc:creator>Prateek Arora</dc:creator>
<dc:creator>Javier Lucas</dc:creator>
<dc:creator>Casie Iciek</dc:creator>
<dc:creator>Laura Lalaguna</dc:creator>
<dc:creator>Enrique Lara-Pezzi</dc:creator>
<dc:creator>Ignacio Flores</dc:creator>
<dc:creator>Nadia Mercader</dc:creator>
<dc:date>2025-03-31</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Paternal Cardiac Lesion Induces Cardiac Adaptation in Offspring</dc:title>
<dc:identifier>pmid:40163557</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.070323</dc:identifier>
</item>
<item>
<title>From the Literature</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40163556/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250401101145&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2025 Apr;151(13):966-967. doi: 10.1161/CIRCULATIONAHA.125.074395. Epub 2025 Mar 31.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40163556/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250401101145&v=2.18.0.post9+e462414">40163556</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.125.074395>10.1161/CIRCULATIONAHA.125.074395</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40163556</guid>
<pubDate>Mon, 31 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Tracy Hampton</dc:creator>
<dc:date>2025-03-31</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>From the Literature</dc:title>
<dc:identifier>pmid:40163556</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.125.074395</dc:identifier>
</item>
<item>
<title>Highlights From the &lt;em>;Circulation&lt;/em>; Family of Journals</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40163551/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250401101145&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Dec 3;150(23):1898-1903. doi: 10.1161/CIRCULATIONAHA.124.072974. Epub 2024 Dec 2.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40163551/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250401101145&v=2.18.0.post9+e462414">40163551</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.072974>10.1161/CIRCULATIONAHA.124.072974</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40163551</guid>
<pubDate>Mon, 31 Mar 2025 06:00:00 -0400</pubDate>
<dc:date>2025-03-31</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Highlights From the &lt;em>;Circulation&lt;/em>; Family of Journals</dc:title>
<dc:identifier>pmid:40163551</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.072974</dc:identifier>
</item>
<item>
<title>Cardiovascular Health Among Rural and Urban US Adults-Healthcare, Lifestyle, and Social Factors</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40163358/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250401101145&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS AND RELEVANCE: This national cross-sectional study found substantial rural-urban disparities in cardiometabolic risk factors and cardiovascular diseases, which were largest among younger adults and almost entirely explained by social risk factors. These findings suggest that efforts to improve socioeconomic conditions in rural communities may be critical to address the rural-urban gap in cardiovascular health.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2025 Mar 31. doi: 10.1001/jamacardio.2025.0538. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: Improving cardiovascular health in rural areas is a national priority in the US. However, little is known about the current state of rural cardiovascular health and the underlying drivers of any rural-urban disparities.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To compare rates of cardiometabolic risk factors and cardiovascular diseases between rural and urban US adults and to evaluate the extent to which health care access, lifestyle factors, and social risk factors contribute to any rural-urban differences.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: This nationally representative cross-sectional study analyzed data from US adults aged 20 years or older residing in rural vs urban areas using the 2022 National Health Interview Survey. Data were analyzed between August 2024 and February 2025.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">EXPOSURE: County-level rurality.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: The primary outcomes were age-standardized rates of cardiometabolic risk factors (hypertension, hyperlipidemia, obesity, and diabetes) and cardiovascular diseases (coronary heart disease [CHD] and stroke).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: The study population consisted of 27 172 adults, including 4256 adults (14.0%) residing in rural areas, 14 741 (54.8%) in small or medium metropolitan areas, and 8175 (31.2%) in urban areas. Mean (SD) participant age was 49.1 (17.8) years, and 4399 participants (50.8%) were female. Compared with their urban counterparts, rural adults were more likely to smoke, be insufficiently physically active, and have more social risk factors. Age-standardized rates of cardiometabolic risk factors were significantly higher in rural areas, including hypertension (37.1% vs 30.9%; rate ratio [RR], 1.20; 95% CI, 1.13-1.27), hyperlipidemia (29.3% vs 26.7%; RR, 1.10; 95% CI, 1.03-1.18), obesity (41.1% vs 30.0%; RR, 1.37; 95% CI, 1.27-1.47), and diabetes (11.2% vs 9.8%; RR, 1.15; 95% CI, 1.02-1.29). The same pattern was observed for CHD (6.7% vs 4.3%; RR, 1.58; 95% CI, 1.35-1.85), but no differences were observed for stroke. The magnitude of rural-urban disparities was largest among young adults (aged 20-39 years) for hypertension (RR, 1.44; 95% CI, 1.12-1.86), obesity (RR, 1.54; 95% CI, 1.34-1.77), and diabetes (RR, 2.59; 95% CI, 1.54-4.38). Rural-urban disparities in cardiovascular health were not meaningfully attenuated after adjustment for measures of health care access (insurance coverage, usual source of care, and recent health care utilization) and lifestyle factors (smoking and physical activity). However, accounting for social risk factors (poverty, education level, food insecurity, and home ownership) completely attenuated rural-urban disparities in hypertension (adjusted RR [aRR], 0.99; 95% CI, 0.93-1.06), diabetes (aRR, 1.02; 95% CI, 0.90-1.15), and CHD (aRR, 1.08; 95% CI, 0.91-1.29), but only partially attenuated disparities in obesity (aRR, 1.29; 95% CI, 1.20-1.39).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: This national cross-sectional study found substantial rural-urban disparities in cardiometabolic risk factors and cardiovascular diseases, which were largest among younger adults and almost entirely explained by social risk factors. These findings suggest that efforts to improve socioeconomic conditions in rural communities may be critical to address the rural-urban gap in cardiovascular health.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40163358/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250401101145&v=2.18.0.post9+e462414">40163358</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2025.0538>10.1001/jamacardio.2025.0538</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40163358</guid>
<pubDate>Mon, 31 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Michael Liu</dc:creator>
<dc:creator>Lucas X Marinacci</dc:creator>
<dc:creator>Karen E Joynt Maddox</dc:creator>
<dc:creator>Rishi K Wadhera</dc:creator>
<dc:date>2025-03-31</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Cardiovascular Health Among Rural and Urban US Adults-Healthcare, Lifestyle, and Social Factors</dc:title>
<dc:identifier>pmid:40163358</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2025.0538</dc:identifier>
</item>
<item>
<title>Rural America-Expanding the Lens of Health Disparities: Endorsing the Need for Health Equity Research</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40163356/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250401101145&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2025 Mar 31. doi: 10.1001/jamacardio.2025.0555. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40163356/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250401101145&v=2.18.0.post9+e462414">40163356</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2025.0555>10.1001/jamacardio.2025.0555</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40163356</guid>
<pubDate>Mon, 31 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Sadiya S Khan</dc:creator>
<dc:creator>Clyde W Yancy</dc:creator>
<dc:date>2025-03-31</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Rural America-Expanding the Lens of Health Disparities: Endorsing the Need for Health Equity Research</dc:title>
<dc:identifier>pmid:40163356</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2025.0555</dc:identifier>
</item>
<item>
<title>Mining the Electronic Medical Record for Hypertension Treatment-Hope or Hype?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40162966/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250401101145&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2025 Mar 31. doi: 10.1001/jamacardio.2025.0842. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40162966/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250401101145&v=2.18.0.post9+e462414">40162966</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2025.0842>10.1001/jamacardio.2025.0842</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40162966</guid>
<pubDate>Mon, 31 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Sadiya S Khan</dc:creator>
<dc:date>2025-03-31</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Mining the Electronic Medical Record for Hypertension Treatment-Hope or Hype?</dc:title>
<dc:identifier>pmid:40162966</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2025.0842</dc:identifier>
</item>
<item>
<title>Leveraging Preexisting Cardiovascular Data to Improve the Detection and Treatment of Hypertension: The NOTIFY-LVH Randomized Clinical Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40162953/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250401101145&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS AND RELEVANCE: In the NOTIFY-LVH randomized clinical trial, a centralized population health coordinator-led notification and clinical support pathway for individuals with LVH on prior echocardiograms increased the initial treatment of hypertension. This work highlights the potential benefit of leveraging preexisting but potentially underutilized cardiovascular data to improve health care delivery through mechanisms augmenting the traditional ambulatory care system.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2025 Mar 31. doi: 10.1001/jamacardio.2025.0871. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: Hypertension is often underrecognized, leading to preventable morbidity and mortality. Tailored data systems combined with care augmented by trained nonphysicians have the potential to improve cardiovascular care.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To determine whether previously collected cardiovascular imaging data could be harnessed to improve the detection and treatment of hypertension through a system-level intervention.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: The NOTIFY-LVH trial was a 2-arm, pragmatic randomized clinical trial conducted from March 2023 through June 2024 within the Mass General Brigham health care system, a multi-institutional network serving the greater Boston, Massachusetts, area. The study included individuals with a Mass General Brigham primary care affiliation who had left ventricular hypertrophy (LVH) on a prior echocardiogram, had no established cardiomyopathy diagnosis, and were not being treated with antihypertensive medications. Patients were followed for 12 months postintervention.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">INTERVENTION: Population health coordinators contacted clinicians of patients randomized to the intervention, notifying them of LVH and offering assistance with follow-up care. A clinical support pathway-including 24-hour ambulatory blood pressure monitoring or cardiology referrals-was provided to aid LVH evaluation.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: The primary outcome was the initiation of an antihypertensive medication. Secondary outcomes included new hypertension and cardiomyopathy diagnoses.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: A total of 648 patients were randomized-326 to the intervention and 322 to the control. Mean (SD) patient age was 59.4 (10.8) years and 248 patients (38.3%) were female. A total of 102 patients (15.7%) had a baseline diagnosis of hypertension and 109 patients (20.1%) had a mean outpatient blood pressure of 130/80 mm Hg or higher. Over 12 months, 53 patients (16.3%) in the intervention arm were prescribed an antihypertensive medication vs 16 patients (5.0%) in the control arm (adjusted odds ratio [OR], 3.76; 95% CI, 2.09-6.75; P &lt; .001). Individuals in the intervention group were also more likely to be diagnosed with hypertension (adjusted OR, 4.43; 95% CI, 2.36-8.33; P &lt; .001). Cardiomyopathy diagnoses did not significantly differ between groups.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: In the NOTIFY-LVH randomized clinical trial, a centralized population health coordinator-led notification and clinical support pathway for individuals with LVH on prior echocardiograms increased the initial treatment of hypertension. This work highlights the potential benefit of leveraging preexisting but potentially underutilized cardiovascular data to improve health care delivery through mechanisms augmenting the traditional ambulatory care system.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT05713916.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40162953/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250401101145&v=2.18.0.post9+e462414">40162953</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2025.0871>10.1001/jamacardio.2025.0871</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40162953</guid>
<pubDate>Mon, 31 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Adam N Berman</dc:creator>
<dc:creator>Michael K Hidrue</dc:creator>
<dc:creator>Curtis Ginder</dc:creator>
<dc:creator>Linnea Shirkey</dc:creator>
<dc:creator>Japneet Kwatra</dc:creator>
<dc:creator>Anna C O'Kelly</dc:creator>
<dc:creator>Sean P Murphy</dc:creator>
<dc:creator>Jennifer M Searl Como</dc:creator>
<dc:creator>Danielle Daly</dc:creator>
<dc:creator>Yee-Ping Sun</dc:creator>
<dc:creator>William T Curry</dc:creator>
<dc:creator>Marcela G Del Carmen</dc:creator>
<dc:creator>Ron Blankstein</dc:creator>
<dc:creator>John A Dodson</dc:creator>
<dc:creator>David A Morrow</dc:creator>
<dc:creator>Benjamin M Scirica</dc:creator>
<dc:creator>Niteesh K Choudhry</dc:creator>
<dc:creator>James L Januzzi</dc:creator>
<dc:creator>Jason H Wasfy</dc:creator>
<dc:date>2025-03-31</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Leveraging Preexisting Cardiovascular Data to Improve the Detection and Treatment of Hypertension: The NOTIFY-LVH Randomized Clinical Trial</dc:title>
<dc:identifier>pmid:40162953</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2025.0871</dc:identifier>
</item>





























</channel>
</rss>